Cytodyn - biotech mit Monster Potential !!
https://seekingalpha.com/news/...dyn-down-32-on-bearish-citron-report
Wir haben aufgrund unserer DD's ein entsprechendes risikoprofil zum wert mit eventuellen austrittswahrscheinlichkeiten.
Und jeder hat dabei ein eigenes risiko empfinden.
Optionen
| Boardmail an "Xarope" |
Wertpapier: CytoDyn Inc |
Da reagiert man also auch.
Die an den Beatmungsgeräten hängen haben nichts davon, nur wenn man gleich am Anfang der Krankheit Remdesivir gibt kann (aber muß nicht) sich der Zustand verbessern, so der aktuelle Forschungs bzw. Ergebnisstand von einigen Kliniken die Remdesivir geben - aber wenn es keines mehr gibt und der Trump alles in seinem Keller gebunkert hat ist es auch nicht mehr lange hin bis keiner mehr damit forschen kann. Soll er glücklich werden damit.
Short Attacke oder Wahrheit?
Oder beides? Spätestens seit Wirecard sollte man hellhörig werden, wenn short-seller Witterung aufgenommen haben. Bin auch eher skeptisch was CYDY angeht und betrachte das Spektakel von der Seitenlinie.
https://seekingalpha.com/news/...dyn-down-32-on-bearish-citron-report
Optionen
| Boardmail an "Vassago" |
Wertpapier: CytoDyn Inc |
Ich kann das so sehen, wie wenn ich einen Teil meiner Gewinne für die Jugendarbeit gespendet hätte :)
Optionen
| Boardmail an "Vermeer" |
Wertpapier: CytoDyn Inc |
Und über diesen Shortseller erfährt man nicht unbedingt gute Sachen.
Optionen
| Boardmail an "Xarope" |
Wertpapier: CytoDyn Inc |
Wenn sie es schaffen die Anlegergemeinde misstrauisch zu machen und den Schwung abzuwürgen, haben sie meist ihr Ziel erreicht. Doch angesichts der dramatischen COVID19 - Erkrankungen und weiterhin zunehmenden Ansteckungen weltweit, insbesondere auf dem amerikanischen Kontinent, wird die Einsatznotwendigkeit des Medikamentes von CYDY zunehmen.
Bleibe voll investiert!
Optionen
| Boardmail an "bauwi" |
Wertpapier: CytoDyn Inc |
https://seekingalpha.com/news/...-citron-pulls-bearish-cytodyn-report
Nicht nur die Kurse , auch die Zeit läuft Citron nun davon, da gute Nachrichten nicht mehr allzu lange auf sich warten lassen.
Optionen
| Boardmail an "bauwi" |
Wertpapier: CytoDyn Inc |
https://www.youtube.com/watch?v=TwdjWhWV1nc&feature=youtu.be
Von der Öffentlichkeitsarbeit scheint CYDY das genaue Gegenteil von dem zu sein, was hierzulande von einem anderen Unternehmen mitbekommen hat. Ich glaube da ging es um Zahlungsabwicklung im Internet oder so...
Dem Interview nach ist ja nichts dran an der Sche, was sagt ihr?
Optionen
| Boardmail an "Tommy2015" |
Wertpapier: CytoDyn Inc |
Ich mach das so, dass ich meine Eingeweide die Entscheidungen treffen lasse.
Solange der Zustand deiner Eingeweide nicht mit "der Stimmung im Forum" zusammengeschaltet ist, hast du gute Chancen, dass da öfter die richtige Entscheidung rauskommt. Aber sowieso nicht jedesmal.
Optionen
| Boardmail an "Vermeer" |
Wertpapier: CytoDyn Inc |
Welchen Broker könnt ihr mehr empfehlen ?
Ich schaffe hier konstant immer mal etwas Geld beiseite und kauf sobald es geht ein bisschen was für billiges Geld zurück, das ging hier bisher sehr gut, und man ist irgendwann sowieso aus dem Schneider.
Optionen
| Boardmail an "Vermeer" |
Wertpapier: CytoDyn Inc |
CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology
Download as PDFJuly 02, 2020 6:00am EDT
VANCOUVER, Washington, July 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the public release of the animation for leronlimab in immuno-oncology. Click here to view the animation.
CytoDyn is encouraged by the potential of leronlimab to positively influence the tumor microenvironment by inhibiting T-reg infiltration, conversion of M2 macrophages (protumor macrophages) into M1 macrophages (antitumor macrophages), decreasing tumor angiogenesis, and inhibiting metastasis through CCR5 overexpression.
CytoDyn is currently exploring the efficacy of leronlimab for several immuno-oncology indications, including metastatic triple-negative breast cancer, a mechanism of action basket trial for 22 solid tumors, and a Phase 2 combination therapy for metastatic colorectal cancer. The FDA has granted leronlimab Fast Track designation for metastatic triple-negative breast cancer.
“We appreciate the work of Nucleus Medical Media to capture the potential benefits of leronlimab in the tumor microenvironment. The control of the tumor microenvironment is critical in the ultimate determination of clinical patient outcomes. We believe leronlimab may help leverage the immune system’s natural ability to fight cancer. Leronlimab’s safety profile and potential synergistic effects with current oncology treatments may prove to be an exciting opportunity within immuno-oncology,” said Scott A. Kelly, M.D., Chief Medical Officer and Chairman of the Board of CytoDyn.
About Coronavirus Disease 2019
CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.
About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy
The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May 11, 2020. After the FDA deems a BLA submission complete, it sets a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA. The Company filed a request for Priority Review designation for its BLA to shorten the FDA’s review time from 10 to 6 months, an FDA goal for BLA applications given Priority Review designation.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.
About CytoDyn
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.